Vivere Oncotherapies
“As a founding team with strong connections to Berkeley, we share California Innovation Fund’s vision to create a healthier world and give back to the UC community. We’re grateful to have their support as we work to advance our products to benefit cancer patients for which there are not effective standards of care.”
- Melissa Kotterman, CEO
Vivere Oncotherapies is co-founded by UC Berkeley professors, staff, postdocs, and graduate students. The team is developing best-in-class, IV-administered oncotherapy products with improved delivery, efficacy, and safety for the treatment of solid cancers using a proprietary discovery platform. Vivere’s experienced leadership team is applying their novel protein engineering platform to generate improved delivery vehicles that can selectively replicate within and kill tumors, mediate multi-antigen targeting of immune cells to the tumor, and express multiple cargoes to stimulate the immune response and overcome the immunosuppressive environment of cold tumors. Vivere believes that this technology will benefit patients with cold, solid tumors for which there are not effective standards of care.
